ADCC Antibody Team at Creative Biolabs Announces Therapeutic Fc Characterization Services
Focusing on ADCC enhancement therapeutic Fc engineering services, Creative Biolabs now offers a broad range of therapeutic Fc characterization services to facilitate biobetter or biosimilar therapy development.
New York, United States – October 26, 2021 /MarketersMEDIA/ —
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest-growing drugs in recent years, with approvals for a variety of indications ranging from cancer to autoimmune disease. The Fc domain is essential to the functioning of an antibody and has been the emphasis of many engineering endeavors. One of the major mechanisms of action for anti-tumor therapeutic antibodies is the targeted killing of tumor cells via recruitment of the immune system, which itself is achieved through the interaction of the Fc domain with the complement component C1q, Fc-Gamma receptors (FcγR), or neonatal Fc receptor (FcRn).
Creative Biolabs has specialized in the development of antibody treatments for many years and now offers a broad range of therapeutic Fc characterization services to promote the creation of biobetter or biosimilar therapies. Pre-developed, pre-validated assays for evaluating the binding of C1q, FcγR, or FcRn are available for the most common isotypes of therapeutic mAbs, and can be used for early testing, enabling quicker and more cost-effective characterization of the Fc region of the molecule.
Creative Biolabs provides C1q binding assay services to support the production, process development, characterization and other related studies of therapeutic antibodies and Fc fusion proteins. The scientist team has successfully generated a sensitive Biacore assay for C1q that can detect differences in glycosylation and has developed a C1q-binding ELISA platform for extensive testing and identification of mAbs.
For FcγR binding assay services, Creative Biolabs is skillful in using Biacore T200 and 4000 systems for various IgG antibody isotypes or Fc fusion proteins. The service portfolio includes the selection of appropriate coupling strategies to capture antibodies or Fc receptors and qualitative and quantitative kinetic analysis of FcγR/ FcRn interaction.
In addition, ready-to-use FcRn binding assays based on SPR and Biacore T200 platform is available at Creative Biolabs. Clients can also find FcRn binding to the most common toxicology species. The binding of cynomolgus monkey, rat and mouse FcRn to human IgG or fusion protein can be demonstrated and compared with the binding to human FcRn.
The accumulated experience in method development and qualification makes Creative Biolabs a reliable support from clone ranking and drug candidate selection to the clinical stage. Detailed information can be found on https://adcc.creative-biolabs.com/.
About Creative Biolabs
With more than a decade of exploration and expansion, Creative Biolabs has gathered a team of experts with solid knowledge regarding ADCC/CDC-enhanced therapeutic antibody discovery and development. Powered by Afuco™ technology, Creative Biolabs is confident to provide fully integrated solutions of expression optimization, recombinant protein production, antibody ADCC/CDC modification design, or cell line development.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://adcc.creative-biolabs.com/
Source: MarketersMEDIA
Release ID: 89050630
Copyright © 1999-2013 SproutNews.com
